Targeted Cdkn2a Suppression Therapy to Prevent Muscle Stem Cell Aging in SMA and Myopathies

This technology is a gene-targeting therapeutic approach that suppresses Cdkn2a expression to prevent premature muscle stem cell aging for spinal muscular atrophy (SMA) and other myopathies.

Unmet Need: Improving muscle preservation in SMA and myopathy therapies

The current standard of care for spinal muscular atrophy (SMA) primarily focuses on restoring survival motor neuron (SMN) protein levels, which addresses motor neuron dysfunction but fails to adequately target muscle degeneration caused by intrinsic muscle stem cell defects. Without addressing these defects, disease progression persists, leading to diminished therapeutic outcomes and quality of life. There is a critical need for treatments that directly preserve muscle function and prevent degeneration to complement existing SMA therapies and more effectively combat myopathy.

The Technology: Targeted Cdkn2a suppression to prevent muscle degeneration

This technology leverages gene-targeting interventions, such as siRNAs and Gapmers, to suppress Cdkn2a expression, effectively reducing RNA and protein levels associated with muscle stem cell senescence. By restoring the self-renewal capacity of muscle satellite cells, it prevents premature aging and exhaustion of these cells, addressing a key contributor to muscle degeneration in conditions like SMA and other myopathies.

This technology has been validated in mice models.

Applications:

Therapeutics for SMA and other myopathies
Drug screening for Cdkn2a-related muscle stem cell senescence
Combine therapy involving SMN protein restoration and Cdkn2a suppression
Research tool for investigating the role of Cdkn2a in muscle stem cell biology
Studying muscle regeneration mechanisms in degenerative diseases

Advantages:

Complementary approach
Broad applicability
Non-invasive delivery potential
Cost-effective

Lead Inventor:

Umrao R. Monani, Ph.D.

Patent Information:

Patent Pending(US19/422,180)

Patent Pending(WO/2024/263971)

Related Publications:

Kim JK, Jha NN, Awano T, Caine C, Gollapalli K, Welby E, Kim SS, Fuentes-Moliz A, Wang X, Feng Z, Sera F, Takeda T, Homma S, Ko CP, Tabares L, Ebert AD, Rich MM, Monani UR. “A spinal muscular atrophy modifier implicates the SMN protein in SNARE complex assembly at neuromuscular synapses” Neuron. 2023 May 3; 111(9): 1423-1439.

Tech Ventures Reference:

IR CU23330
Licensing Contact: Kristin Neuman